2026欧洲肿瘤内科学会年会（ESMO Congress 2026）将于10月23日~27日举行。目前ESMO官方已公布本届会议的口头报告标题及讲者信息。【肿瘤资讯】特此整理消化道肿瘤领域的18项LBA研究，以飨读者。
胃食管癌
Presidential Symposium session
摘要号：LBA7
中文标题：CLARITY-Gastric 01 (CG-01)：一项 3 期研究，评估 sonesitatug vedotin (Sone-Ve) 在二线或后续 (2L+) 治疗中对 Claudin 18.2 (CLDN18.2) 阳性晚期或转移性胃食管癌 (GEC) 的疗效
英文标题：CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)
讲者：徐瑞华（中国广州）
Proffered Paper session
摘要号：LBA77
中文标题：Arcotatug tavatecan（IBI343/TAK-921）对比医生选择的治疗方案（TPC）用于既往接受过治疗的晚期胃癌或胃食管交界处腺癌（G/GEJA）：随机、开放标签、III期G-HOPE-001研究的首次中期分析
英文标题：Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician's choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study
讲者：Kohei Shitara（Kashiwa, Japan, Chiba）
摘要号：LBA78
中文标题：食管癌新辅助放化疗后主动监测对比标准手术：整群随机对照试验（SANO）的长期结果
英文标题：Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO)
讲者：Sanjiv S. Gangaram-Panday（Rotterdam, Netherlands）
Rapid Oral session
摘要号：LBA80
中文标题：安尼妥单抗联合化疗治疗既往接受过治疗的HER2阳性胃癌或胃食管交界处癌（GC/GEJC）：KC-WISE研究更新的总生存期（OS）分析
英文标题：Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
讲者：徐建明（中国北京）
摘要号：LBA81
中文标题：II~IIIB期胃癌辅助XELOX方案4个月对比6个月——LOMAC随机试验
英文标题：Four Months of Adjuvant XELOX versus Six Months in Stage II–IIIB Gastric Cancer — The LOMAC Randomized Trial
讲者：徐大志（中国上海）
肝胆胰肿瘤
Presidential Symposium session
摘要号：LBA8
中文标题：依沃西单抗联合化疗与度伐利尤单抗联合化疗作为晚期胆道癌一线治疗：一项随机、对照、双盲、3 期试验（HARMONi-GI1）
英文标题：Ivonescimab plus chemotherapy versus durvalumab plus chemotheray as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double- blinded, phase 3 trial (HARMONi-GI1)
讲者：周俭（中国上海）
Proffered Paper session
摘要号：LBA21
中文标题：吉西他滨联合顺铂辅助化疗对比标准治疗用于胆管癌和胆囊癌根治性切除术后（ACTICCA-1试验）
英文标题：Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial)
讲者：Henning Wege（Hamburg, Germany）
摘要号：LBA48
中文标题：III期EMERALD-3研究中肝功能轨迹及进展后结局：曲麦利尤单抗（T）+度伐利尤单抗（D）±仑伐替尼（L）+经动脉化疗栓塞（TACE）治疗适合栓塞的肝细胞癌（eeHCC）
英文标题：Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC)
讲者：Masatoshi Kudo（Osaka, Japan）
摘要号：LBA82
中文标题：RAS(ON)多选择性抑制剂Daraxonrasib对比化疗用于既往接受过治疗的转移性胰腺导管腺癌（mPDAC）：III期RASolute 302研究的其他亚组分析
英文标题：Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the Ph3 RASolute 302 study
讲者：Zev A. Wainberg（Los Angeles, United States of America）
摘要号：LBA83
中文标题：七价mKRAS特异性淋巴结靶向两亲性免疫治疗对比观察用于已切除胰腺导管腺癌（PDAC）：AMPLIFY-7P随机II期研究
英文标题：Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study
讲者：Eileen M. O'Reilly（New York, United States of America）
Rapid Oral session
摘要号：LBA84
中文标题：双药对比单药治疗一线治疗失败的晚期胰腺癌患者：一项随机、多中心、开放标签、双臂III期研究（Panc-SELECT——吉西他滨组）
英文标题：A randomized, multicenter, open-label, double-arm, phase III study of doublet vs. monotherapy in advanced pancreatic cancer patients who have failed first-line therapy. (Panc-SELECT - Gemcitabine arms)
讲者：Prabhat G. Bhargava（Mumbai, India）
摘要号：LBA85
中文标题：HRS-4642联合化疗±阿得贝利单抗作为KRAS G12D突变型胰腺癌围手术期治疗：一项II期研究的初步结果
英文标题：HRS-4642 Plus Chemotherapy ± Adebrelimab as Perioperative Therapy in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results of a Phase 2 Study
讲者：沈柏用（中国上海）
摘要号：LBA22
中文标题：OPTIMUM：奥拉帕利（Ola）±度伐利尤单抗（Durva）维持治疗DDR基因突变晚期胆道癌（aBTC）的随机II期研究
英文标题：OPTIMUM: A randomized phase 2 study of maintenance olaparib (Ola) with or without durvalumab (Durva) in DDR gene-mutated advanced biliary tract cancer (aBTC)
讲者：Changhoon Yoo（Seoul, Republic of Korea, Songpa-gu）
肠癌
Proffered Paper session
摘要号：LBA29
中文标题：IROCAS：mFOLFIRINOX对比mFOLFOX6辅助治疗强化用于高危III期（T4和/或N2）结肠癌的随机III期试验
英文标题：IROCAS: A randomized phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III (T4 and/or N2) colon cancer
讲者：Jaafar Bennouna（Suresnes, France）
摘要号：LBA30
中文标题：ω-3多不饱和脂肪酸二十碳五烯酸（EPA）对比安慰剂用于结直肠癌肝转移切除术后（EMT2）：一项多中心、双盲、随机III期试验
英文标题：Omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) versus placebo after resection of colorectal cancer liver metastases (EMT2): A multicentre, double-blind, randomised phase 3 trial
讲者：Mark A. Hull（Leeds, United Kingdom）
摘要号：LBA87
中文标题：Dostarlimab单药治疗dMMR/MSI-H局部晚期直肠癌（LARC）获得临床完全缓解：全球注册性AZUR-1研究首次结果
英文标题：Clinical Complete Response With Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer (LARC): First Results From the Global Registrational AZUR-1 Trial
讲者：Andrea Cercek（New York, United States of America, NY）
Rapid Oral session
摘要号：LBA31
中文标题：双周方案对比常规曲氟尿苷替匹嘧啶联合贝伐珠单抗用于难治性转移性结直肠癌：实用性III期PRABITAS试验
英文标题：Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial
讲者：Hiroya Taniguchi（Nagoya, Japan, Aichi）
摘要号：LBA32
中文标题：CheckMate 8HW最终总生存结果：纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗或化疗用于MSI-H/dMMR转移性结直肠癌
英文标题：Final overall survival results from CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer
讲者：Sara Lonardi（Padua, Italy）
如有错漏之处，敬请留言补充！
排版编辑：肿瘤资讯-古木
苏公网安备32059002004080号
